Bexion Pharmaceuticals Convenes Clinical Advisory Board

FOR IMMEDIATE RELEASE Covington, KY ~ April 2, 2019 

Bexion Pharmaceuticals, Inc. (Bexion) announced today that the company has assembled a Clinical Advisory Board (CAB). The CAB is comprised of Key Opinion Leaders (KOLs) in various Oncology specialties. Their purpose is to review and provide expert guidance on the overall clinical development plan, including designs and implementation of proposed clinical studies. Members include:

Manmeet Ahluwalia, MD, FACP

Manmeet Ahluwalia, MD, FACP is the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) at the Cleveland Clinic Taussig Cancer Institute, where he subspecializes in treatment of patients with brain tumors and brain metastases. He is currently leading several clinical trials involving immune therapy and new targeted therapies as well as treatments targeting tumor blood vessels (angiogenesis) and cancer stem cells. Dr. Ahluwalia received his MD degree from the Maulana Azad Medical College, University of Delhi. He completed his residency at Fairview General Hospital and fellowship training at the Roswell Park Cancer Institute.

Timothy P. Cripe, MD, PhD, FAAP

Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.

Richard C. Curry III, MD

Richard C. Curry III, MD, cares for patients who are navigating through the life-altering journey of brain cancer. His patients and their families can immediately feel comfortable and at ease as he is dedicated to working with them through such a difficult process. Dr. Curry served as Chief Resident for the University of Cincinnati’s Department of Neurology. He received additional training in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Additionally, he has volunteered for several global organizations, treating neurological diseases and setting up medical clinics in local villages.

Olivier Rixe, MD, PhD

Olivier Rixe, MD, PhD, moved to New Mexico in 2014 when he was recruited to serve as the Cancer Center Associate Director for Clinical Research and the Director of the Experimental Therapeutics Unit at the University of New Mexico Cancer Center. While there, he was named the Dana Wood Endowed Chair in Cancer Therapeutics and Early Phase Clinical Research. He recently joined the Santa Fe Cancer Center where he is leading the Experimental Therapeutics Program. He previously worked at the Gustave-Roussy Institute, Pierre and Marie Curie/Sorbonne University, the National Cancer Institute, and the University of Cincinnati Cancer Institute. He has published more than 140 papers in clinical and translational oncology research. His most recent passion is a larger vision of the oncology practice, searching for a better holistic care and a fusion of scientific evidences with spiritual healing, from preventive medicine to treatment of advanced cancer care.

“We are very honored and gratified Bexion has attracted this group of world-renowned oncology investigators to advise us on advancing Bexion’s lead oncology candidate, BXQ-350”, stated Dr. Ray Takigiku, Founder and CEO of Bexion. “We are looking forward to the insights and expertise to be brought by Drs. Ahluwalia, Cripe, Curry, and Rixe as founding members of our CAB.”


About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.   Bexion has completed multi-site first-in-human Phase 1 Parts 1 and 2 clinical studies of BXQ-350 for solid tumors and gliomas. A Phase 1 Part 3 expansion phase study is currently enrolling patients.

For more information, visit


Media Contact: Margaret van Gilse ●859.757.1652


Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

2019-04-05T14:00:51+00:00 April 2nd, 2019|